We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer's radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December ...
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. Online seller eBay to buy ...
Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...
In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s incoming CEO speaks out about the immigration crackdown in the retailer’s ...
WASHINGTON (AP) — Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar ...
Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...
Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...
Pfizer is getting into the obesity treatment industry with a multi-billion-dollar deal for Mestera. Currently, Pfizer and Mestera don’t have an obesity drug on the market. The deal between the two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results